Join this live webinar to learn more.
As emerging biopharma companies look to expand beyond the US market, global launch decisions can either unlock long term value or create irreversible risk. Evolving policy, such as Most Favored Nation (MFN) pricing in the US, combined with various global responses, has made it more critical than ever to accurately predict where the future global market landscape for therapies is headed and to have dynamic launch plans that can adapt with changing regulations and trade policies.
Designed for emerging companies preparing for international expansion, this session offers practical, decision-focused perspectives on getting new global launches right. Drawing on recent global expansion experiences, this session highlights common missteps—such as underestimating the criticality of local evidence requirements, pricing spillover, and business operational complexity—alongside actionable strategies to mitigate them. Attendees will leave with a clear framework for sequencing launches, aligning medical affairs, market access, and commercial strategies, and building strong global operating models.
Offered Free by: Syneos Health
See All Resources from: Syneos Health
